Lataa...
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
PURPOSE: To compare pharmacokinetics, safety, tolerability, and immunogenicity between SB8, a bevacizumab biosimilar, and the European Union (EU) and United States (US) reference products (bevacizumab-EU, bevacizumab-US). METHODS: In this randomized, double-blind, parallel-group, and single-dose stu...
Tallennettuna:
| Julkaisussa: | Cancer Chemother Pharmacol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Berlin Heidelberg
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7515939/ https://ncbi.nlm.nih.gov/pubmed/32949267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04144-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|